Autor segons l'article: Sansa, Aina; Venegas, Maria del Prado; Valero, Cristina; Pardo, Laura; Aviles-Jurado, Francesc-Xavier; Terra, Ximena; Quer, Miquel; Leon, Xavier
Departament: Ciències Mèdiques Bàsiques; Bioquímica i Biotecnologia
Autor/s de la URV: Avilés Jurado, Francisco Javier / Terra Barbadora, Ximena
Paraules clau: Tumor recurrence; Tumor marker; Tobacco use; Retrospective study; Retrospective studies; Recursive partitioning; Radiotherapy; Prognostic factor; Prognosis; Primary tumor; Practice guideline; Neoplasm recurrence, local; Multimodality cancer therapy; Middle aged; Male; Major clinical study; Local recurrence free survival; Humans; Human; Hematological parameters; Head and neck tumor; Head and neck squamous cell carcinoma; Head and neck neoplasms; Follow up; Female; Disease specific survival; Disease control; Controlled study; Cohort analysis; Cisplatin; Chemoradiotherapy; Cetuximab; Carcinoma; Carboplatin; Cancer surgery; Cancer staging; Cancer risk; Cancer classification; Biomarkers, tumor; Ast/alt (deritis) ratio; Ast; Aspartic acid; Aspartate aminotransferases; Aspartate aminotransferase; Aspartate aminotransaminase; Article; Alt (deritis) ratio; Alanine transaminase; Alanine aminotransferase; Alanine aminotransaminase; Alanine; Adult
Resum: Background The aim of this study is to evaluate the relationship between the aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ratio and local disease control in patients with head and neck squamous cell carcinomas (HNSCC) treated with radiotherapy/chemoradiotherapy.
Methods We calculated the pre-treatment AST/ALT ratio in 670 patients with HNSCC treated with radiotherapy (n = 309, 46.1%) or chemoradiotherapy (n = 361, 53.9%).
Results Five-year local recurrence-free survival for patients with a low AST/ALT ratio value (n = 529, 79.0%) was 75.0% (95% CI: 71.1-78.9), and for patients with a high value (n = 141, 21.0%) it was 53.4% (CI 95: 44.4-62.4) (p = 0.0001). In a multivariable analysis, patients with a high ratio had nearly twice the risk of having a local tumor recurrence (HR 1.97, 95% CI 1.42-2.75, p = 0.0001).
Conclusion The AST/ALT ratio was independently associated with the risk of local recurrence in patients with HNSCC treated with radiotherapy or chemoradiotherapy.
Àrees temàtiques: Surgery; Saúde coletiva; Otorhinolaryngology; Odontología; Medicina iii; Medicina ii; Medicina i; Interdisciplinar; General medicine; Farmacia; Engenharias iv; Ciências biológicas iii; Ciências biológicas ii; Ciências biológicas i; Biotecnología
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: franciscojavier.aviles@urv.cat; ximena.terra@urv.cat
Data d'alta del registre: 2024-10-12
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://onlinelibrary.wiley.com/doi/10.1002/hed.26673
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Head And Neck-Journal For The Sciences And Specialties Of The Head And Neck. 43 (7): 2091-2100
Referència de l'ítem segons les normes APA: Sansa, Aina; Venegas, Maria del Prado; Valero, Cristina; Pardo, Laura; Aviles-Jurado, Francesc-Xavier; Terra, Ximena; Quer, Miquel; Leon, Xavier (2021). The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients. Head And Neck-Journal For The Sciences And Specialties Of The Head And Neck, 43(7), 2091-2100. DOI: 10.1002/hed.26673
DOI de l'article: 10.1002/hed.26673
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2021
Tipus de publicació: Journal Publications
Repositori URV